Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial.

Schilling WHK. et al, (2024), PLoS medicine, 21

Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV)

Wongnak P. et al, (2024), The Lancet Infectious Diseases, 24, 953 - 963

Adverse events associated with benznidazole treatment for Chagas disease in children and adults.

Cruz CV. et al, (2024), British journal of clinical pharmacology

Quantifying anti-trypanosomal treatment effects in chronic indeterminate Chagas disease: an individual patient data meta-analysis of two proof of concept trials

Watson JA. et al, (2024)

Phase 2 pilot trial to optimise pharmacometric evaluations in Chagas disease (CHARM: CHAgas disease PharMacometrics)

Cruz CV. et al, (2024), Wellcome Open Research, 9, 342 - 342

Comparison of WHO versus national COVID-19 therapeutic guidelines across the world: not exactly a perfect match.

Cokljat M. et al, (2024), BMJ Glob Health, 9

Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV)

Jittamala P. et al, (2024)

Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial

Luvira V. et al, (2024), BMC Infectious Diseases, 24

An α-Gal antigenic surrogate as a biomarker of treatment evaluation in Trypanosoma cruzi-infected children. A retrospective cohort study.

Abal M. et al, (2024), PLoS neglected tropical diseases, 18

Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial

Schilling WHK. et al, (2024), The Lancet Infectious Diseases, 24, 36 - 45

Clinical Antiviral Efficacy of Remdesivir in Coronavirus Disease 2019: An Open-Label, Randomized Controlled Adaptive Platform Trial (PLATCOV)

Jittamala P. et al, (2023), The Journal of Infectious Diseases, 228, 1318 - 1325

Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open- label, randomised, controlled adaptive platform trial

Luvira V. et al, (2023)

Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV)

Schilling WHK. et al, (2023), eLife, 12

Assessment of the nlmixr R package for population pharmacokinetic modeling: A metformin case study

Mak WY. et al, (2023), British Journal of Clinical Pharmacology, 89, 330 - 339

Clinical antiviral efficacy of remdesivir and casirivimab/imdevimab against the SARS-CoV-2 Delta and Omicron variants

Jittamala P. et al, (2022)

Systematic Review of Early Phase Pediatric Clinical Pharmacology Trials

Subramanian D. et al, (2022), The Journal of Pediatric Pharmacology and Therapeutics, 27, 609 - 617

Pharmacometric assessment of the in vivo antiviral activity of ivermectin in early symptomatic COVID-19

Schilling WHK. et al, (2022)

An Ultrafast Ultrahigh-Performance Liquid Chromatography Coupled With Tandem Mass Spectrometry Method for Cannabidiol Monitoring in Pediatric Refractory Epilepsy

Pérez Montilla CA. et al, (2021), Therapeutic Drug Monitoring, 43, 712 - 717

COVID-19 chemoprevention

Cruz C. and White NJ., (2021), International Journal of Infectious Diseases, 107, 31 - 33

Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; protocol for a randomised, placebo-controlled prophylaxis study (COPCOV)

Schilling WHK. et al, (2020), Wellcome Open Research, 5, 241 - 241

Load More

Include forthcoming?